• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤细胞内在的 RIG-I 信号转导控制免疫原性癌症疗法和检查点抑制剂在小鼠中的协同作用。

Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice.

机构信息

Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

National Centre for Tumor Diseases WERA, Germany.

出版信息

Eur J Immunol. 2021 Jun;51(6):1531-1534. doi: 10.1002/eji.202049158. Epub 2021 Apr 5.

DOI:10.1002/eji.202049158
PMID:33733474
Abstract

Immunogenic cancer therapies, including radiation and hypomethylating agents, such as 5-azacytidine, rely on tumor cell-intrinsic activation of the RNA receptor RIG-I for their synergism with immune checkpoint inhibitors. Possible RIG-I ligands are small nuclear RNA (snRNA) and endogenous retroviral elements (ERV) leaking from the nucleus during programmed cell death.

摘要

免疫原性癌症疗法，包括放疗和低甲基化药物，如 5-氮杂胞苷，依赖于肿瘤细胞内在激活 RNA 受体 RIG-I 与其与免疫检查点抑制剂的协同作用。可能的 RIG-I 配体是在程序性细胞死亡过程中从细胞核泄漏的小核 RNA（snRNA）和内源性逆转录病毒元件（ERV）。

相似文献

1
Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice.肿瘤细胞内在的 RIG-I 信号转导控制免疫原性癌症疗法和检查点抑制剂在小鼠中的协同作用。
Eur J Immunol. 2021 Jun;51(6):1531-1534. doi: 10.1002/eji.202049158. Epub 2021 Apr 5.
2
RIG-I activation is critical for responsiveness to checkpoint blockade.RIG-I 激活对于响应检查点阻断至关重要。
Sci Immunol. 2019 Sep 13;4(39). doi: 10.1126/sciimmunol.aau8943.
3
Melanoma Cell Intrinsic GABA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity.黑色素瘤细胞内在γ-氨基丁酸受体增强通过促进直接和T细胞介导的抗肿瘤活性增强放疗和免疫检查点抑制剂反应。
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):1040-1053. doi: 10.1016/j.ijrobp.2020.10.025. Epub 2020 Oct 24.
4
Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.构建核壳型微针系统以实现黑色素瘤免疫治疗中检查点抑制剂的靶向共递药。
Acta Biomater. 2020 Mar 1;104:147-157. doi: 10.1016/j.actbio.2019.12.037. Epub 2020 Jan 3.
5
Normalization Cancer Immunotherapy for Melanoma.规范化癌症免疫疗法治疗黑色素瘤。
J Invest Dermatol. 2020 Jun;140(6):1134-1142. doi: 10.1016/j.jid.2020.02.005. Epub 2020 Feb 22.
6
RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.RIG-I 激活的免疫刺激性 RNA 增强了抗癌疫苗的疗效，并与免疫检查点阻断协同作用。
EBioMedicine. 2019 Mar;41:146-155. doi: 10.1016/j.ebiom.2019.02.056. Epub 2019 Mar 6.
7
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.现代免疫疗法中的黑色素瘤检查点抑制剂。
Int J Mol Sci. 2020 Mar 30;21(7):2367. doi: 10.3390/ijms21072367.
8
RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma.RIG-I 免疫疗法克服了 p53 阳性恶性黑色素瘤的放射抵抗性。
J Mol Cell Biol. 2023 Jun 1;15(1). doi: 10.1093/jmcb/mjad001.
9
Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy.靶向肿瘤细胞中的核酸传感器，重新编程细胞外囊泡的生物发生和 RNA 货物，用于 T 细胞介导的癌症免疫治疗。
Cell Rep Med. 2023 Sep 19;4(9):101171. doi: 10.1016/j.xcrm.2023.101171. Epub 2023 Aug 31.
10
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade.PRMT7 缺失可激活抗肿瘤免疫并增强黑色素瘤对免疫检查点阻断的敏感性。
Cell Rep. 2022 Mar 29;38(13):110582. doi: 10.1016/j.celrep.2022.110582.

引用本文的文献

1
Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors.靶向细胞内天然RNA传感系统可克服实体瘤对CAR-T细胞疗法的耐药性。
Cancer Res. 2025 Jul 15;85(14):2679-2693. doi: 10.1158/0008-5472.CAN-24-3425.
2
N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma.N-MYC 破坏高级别浆液性卵巢癌中的固有免疫信号转导。
Sci Adv. 2024 May 17;10(20):eadj5428. doi: 10.1126/sciadv.adj5428. Epub 2024 May 15.
3
Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy.
靶向肿瘤细胞中的核酸传感器，重新编程细胞外囊泡的生物发生和 RNA 货物，用于 T 细胞介导的癌症免疫治疗。
Cell Rep Med. 2023 Sep 19;4(9):101171. doi: 10.1016/j.xcrm.2023.101171. Epub 2023 Aug 31.
4
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy.嵌合型水泡性口炎病毒-新城疫病毒的溶瘤病毒疗法协同支持视黄酸诱导基因I依赖的检查点抑制剂免疫疗法。
Mol Ther Oncolytics. 2023 Aug 5;30:117-131. doi: 10.1016/j.omto.2023.08.001. eCollection 2023 Sep 21.
5
Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer.遗传调控免疫和致癌信号通路与肿瘤内在免疫抵抗相关：联合靶向治疗-免疫治疗癌症的分子基础。
Cell Mol Life Sci. 2023 Jan 11;80(2):40. doi: 10.1007/s00018-023-04689-9.
6
Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy.通过联合放疗靶向DNA损伤反应和模式识别受体来增强抗肿瘤先天免疫。
Front Oncol. 2022 Aug 29;12:971959. doi: 10.3389/fonc.2022.971959. eCollection 2022.
7
Emerging role of RNA sensors in tumor microenvironment and immunotherapy.RNA 传感器在肿瘤微环境和免疫治疗中的新作用。
J Hematol Oncol. 2022 Apr 12;15(1):43. doi: 10.1186/s13045-022-01261-z.